Insect sting allergy and venom immunotherapy: A model and a mystery

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

In situ imaging of honeybee (Apis mellifera) venom components from aqueous and aluminum hydroxide–adsorbed venom immunotherapy preparations Ulla Seppälä,

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Mark S. La Shell, MD, Christopher W. Calabria, MD, James M. Quinn, MD

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Alveolar nitric oxide and asthma control in mild untreated asthma

Allergen immunotherapy: A practice parameter third update

Simon G. A. Brown, MBBS, PhD, FACEM, Michael D

Advances in food allergy in 2015

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Advances in pediatric asthma in 2011: Moving forward

Disparities in allergic disease: Hypersensitivity and social disorders

Erika Lerch, MD, Ulrich R. Müller, MD

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

David A. Khan, MD Journal of Allergy and Clinical Immunology

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Jack Pepys' contributions to the medical literature

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Advancing asthma care: The glass is only half full!

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Peter M. Wolfgram, MD, David B. Allen, MD

Administration of a probiotic with peanut oral immunotherapy: A randomized trial Mimi L.K. Tang, PhD, Anne-Louise Ponsonby, PhD, Francesca Orsini, MSc,

Practice Notes from the AAAAI

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Phillip Lieberman, MD, Michael Tankersley, MD

Legends in allergy: Philip S. Norman and Lawrence M

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venom Jörg Fischer, MD, Martin Teufel, MD, Alexandra.

Phillip Lieberman, MD, David Golden, MD

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Natural history of Hymenoptera venom sensitivity in adults

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

Cephalosporin Side Chain Cross-reactivity

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis Thomas B. Casale, MD, William.

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Mark S. La Shell, MD, Christopher W. Calabria, MD, James M. Quinn, MD

New pathways for itching in patients with atopic dermatitis?

Prevention of food allergy: Beyond peanut

Bruce G. Bender, PhD, Alex Pedan, PhD, Laleh T. Varasteh, RPh, MSF

Risk of oral food challenges

Practice Notes from the AAAI

Xiu-Min Li, MD, LaVerne Brown, PhD

Wasp venom immunotherapy expands a subpopulation of CD4+CD25+ forkhead box protein 3–positive regulatory T cells expressing the T-cell receptor Vβ2 and.

Endotoxin and the lung: Insight into the host-environment interaction

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

Asthma progression: Can we and should we measure it?

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously Shilpa H. Desai, BS, MD, Akhil Chouksey, MD, John Poll, RN, Melvin Berger,

The Editors' Choice Journal of Allergy and Clinical Immunology

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Environmental factors and eosinophilic esophagitis

The GILL study: Glycerin-induced local reactions in immunotherapy

Advances in pediatric asthma in 2007

Safety and efficacy of repeated monthly carboplatin desensitization

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

David B. K. Golden, MD, Nancy L. Breisch, PhD, Robert G

Presentation transcript:

Insect sting allergy and venom immunotherapy: A model and a mystery David B.K. Golden, MD Journal of Allergy and Clinical Immunology Volume 115, Issue 3, Pages 439-447 (March 2005) DOI: 10.1016/j.jaci.2005.01.005 Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Photographs showing the honeybee (Apis mellifera; A) and a common species of wasp (Polistes exclamans; B). Reproduced with permission from Vespa-ALK-Abello Labs. Journal of Allergy and Clinical Immunology 2005 115, 439-447DOI: (10.1016/j.jaci.2005.01.005) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 Four dose regimens reported for VIT depicting each dose given during the initial build-up stage of treatment. In the ultrarush schedule (UR-VIT) doses are given every 30 minutes to reach the full dose in 6 hours. In the rush schedule (R-VIT) doses are given every 30 minutes for 10 doses on day 1, 4 doses on day 2, and 2 doses on day 3. The modified rush schedule (MR-VIT) is given once weekly for 8 weeks, and the traditional schedule (T-VIT) is given weekly for 4 months or more. Journal of Allergy and Clinical Immunology 2005 115, 439-447DOI: (10.1016/j.jaci.2005.01.005) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 3 Natural history of insect sting allergy showing the risk of systemic reaction to a sting in untreated patients (solid line) and in patients who received VIT (dashed lines) for a duration of either 1 to 2 years or for a mean of 6 years. Reprinted with permission from Golden DBK, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000;105:389. Journal of Allergy and Clinical Immunology 2005 115, 439-447DOI: (10.1016/j.jaci.2005.01.005) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions